Eisai submits new drug application for subcutaneous Leqembi in Japan
LEQEMBI is a treatment for early Alzheimer’s disease
Read More
Section: Regulatory
Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment
Around 9,000 people in the US currently live with SMA
Read More
Regeneron’s Libtayo receives EC approval for skin cancer
Phase 3 trial results showed the drug significantly improved disease-free survival
Read More
Sandoz launches first and only multiple sclerosis biosimilar in US
The treatment is FDA-approved to treat MS and Crohn’s disease
Read More
J&J receives positive NICE recommendation for multiple myeloma treatment
The treatment is approved for use within the NHS in England and Wales
Read More